Neumora Therapeutics, Inc. Common Stock
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Josh Pinto
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 490 Arsenal Way Watertown MA United States of America 02472
- IPO Date
- Sep 15, 2023
- CIK
- 0001885522
- Website
- neumoratx.com
- Similar Companies
- Business
- Neumora Therapeutics, Inc. Neumora Therapeutics, Inc. (NMRA) is a clinical-stage biopharmaceutical company focused on developing precision medicines for brain diseases through the integration of data science, neuroscience, and novel mechanisms of action targeting central nervous system disorders. Founded in November 2019 and headquartered in Watertown, Massachusetts, the company advances a pipeline of seven clinical and preclinical neuroscience programs for underserved neuropsychiatric disorders including major depressive disorder, schizophrenia, bipolar II disorder, and agitation in Alzheimer's disease, as well as neurodegenerative diseases such as Parkinson's disease, amyotrophic lateral sclerosis, and obesity-related conditions; key candidates include navacaprant (NMRA-140, KOR antagonist), NMRA-511 (V1aR antagonist), NMRA-861 and NMRA-898 (M4 modulators), NMRA-215 (NLRP3 inhibitor), NMRA-GCASE (GCASE activator), and NMRA-CK1δ (CK1δ inhibitor). Neumora operates primarily in the United States with a precision medicine approach emphasizing best-in-class pharmacology for prevalent brain diseases affecting millions globally. In recent developments, the company reported positive preclinical data for NMRA-215 in diet-induced obesity models in October 2025 and plans to initiate its Phase 1 study in the first quarter of 2026; it advanced Phase 1 studies for NMRA-861 and NMRA-898 with a comprehensive franchise update expected by mid-2026, drew an additional $40 million from its $125 million venture debt facility with K2 HealthVentures in 2025 to support operations into 2027, and continues enrollment in a Phase 1b study of NMRA-511 for Alzheimer's agitation while optimizing the navacaprant program for major depressive disorder.
Company News
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail
NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.
Neumora Therapeutics scraps depression drug after two late-stage trial failures
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA)
Neumora Therapeutics: Downgrading After Navacaprant Development Setback
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026